Our Pipeline

APEIRON’s portfolio consists of our marketed product Qarziba® (APN311) and a product pipeline of five immune-oncology (IO) product candidates in clinical and discovery stages as well as two product candidates for respiratory treatment.

Our immune-oncology projects include the Cbl-b projects (APN401, APN431), the GD2 programs (APN301) and the novel IO discovery projects (APN411, APN421).

Our respiratory product APN01, a recombinant enzyme of the Renin Angiotensin System is currently tested for treatment of COVID-19, which further validates APEIRON’s robust pipeline.

Pipeline Chart